← All trials
NCT05527470
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 11, 2022
- Primary completion
- Nov 11, 2025
- Completion date
- Nov 11, 2027
- First posted
- Sep 2, 2022
- Last posted
- Nov 3, 2022
- Enrollment
- 440
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guilin UniversityLead sponsor
- Guilin UniversitySponsor investigator
- Laibin people's HospitalCollaborator
- Lingshan people's HospitalCollaborator
- Nanxishan Hospital of Guangxi Zhuang Autonomous RegionCollaborator
- Wuzhou Red Cross HospitalCollaborator
- Guangxi Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.